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Influenza A viruses (IAV) are known to modulate and “hijack” several cellular host 
mechanisms, including gene splicing and RNA maturation machineries. These modulations 
alter host cellular responses and enable an optimal expression of viral products throughout 
infection. The interplay between the host protein p53 and IAV, in particular through the viral 
nonstructural protein NS1, has been shown to be supportive for IAV replication. However, it 
remains unknown whether alternatively spliced isoforms of p53, known to modulate p53 
transcriptional activity, are affected by IAV infection and contribute in IAV replication. Using 
a TP53 minigene, which mimics intron 9 alternative splicing, we have shown here that the NS1 
protein of IAV changes the expression pattern of p53 isoforms. Our results demonstrated that 
CPSF4 (cellular protein cleavage and polyadenylation specificity factor 4) independently and 
the interaction between NS1 and CPSF4 modulate the alternative splicing of TP53 transcripts 
which may result in the differential activation of p53 responsive genes. Finally, we reported 
that CPSF4 and most likely beta and gamma spliced p53 isoforms affect both viral replication 
and IAV-associated type I interferon secretion. Altogether, our data showed that cellular p53 
and CPSF4 factors, both interacting with viral NS1, have a crucial role during IAV replication 
that allows IAV to interact and alter the expression of alternatively spliced p53 isoforms in order 
to regulate the cellular innate response, especially via type I interferon secretion, and perform 
efficient viral replication.    
Importance  
  
Influenza A viruses (IAV) constitute a major public health issue, causing illness and death in 
high-risk populations during seasonal epidemics or pandemics. IAV are known to modulate 
cellular pathways to promote their replication and avoid immune restriction via the targeting of 
several cellular proteins. One of these proteins, p53, is a master regulator involved in a large 
panel of biological processes, including cell cycle arrest, apoptosis or senescence. This  
“cellular gatekeeper” is also involved in the control of viral infections, and viruses have 
developed a wide diversity of mechanisms to modulate/hijack p53 functions to achieve an 
optimal replication in their hosts. Our group and others have previously shown that p53 activity 
was finely modulated by different multi-level mechanisms during IAV infection. Here, we 
characterized IAV non-structural protein NS1 and the cellular factor CPSF4 as major partners 
involved in the IAV-induced modulation of the TP53 alternative splicing that was associated 
with a strong modulation of p53 activity and notably the p53-mediated antiviral response.   
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Introduction  
  
Influenza A viruses (IAV) constitute a major public health issue, causing illness and death in 
high-risk populations during seasonal epidemics or pandemics (1, 2). IAV belong to the family 
Orthomyxoviridae of enveloped viruses and contain a segmented genome of singlestranded 
negative-sense RNA (3). In contrast to most RNA viruses, IAV have a nuclear infectious cycle, 
therefore requiring direct access to numerous nuclear host factors and machineries to 
successfully achieve their replication (4). These viruses have notably developed mechanisms to 
reassign the host spliceosome to simultaneously alter host cellular expression and enable an 
optimal expression of specific spliced viral products throughout infection (reviewed in (5)). 
Although the regulation of viral splicing has been extensively studied, the intricate interactions 
between IAV and the host spliceosome, as well as the host splicing regulators, remain to be 
further deciphered.  
Among IAV proteins, the non-structural NS1 is known to be a key “multi-tool” protein with 
which the virus can extensively alter the host-cell responses (6-9). Indeed, NS1 can counteract 
the antiviral interferon (IFN) response using several mechanisms (6-8). In particular, NS1 acts 
as a modulator of numerous cellular host processes, including mRNA processing (5, 10), 
nuclear trafficking/export (11, 12) and translation (13, 14). These multiple accessory functions 
are well illustrated by the considerable number of NS1 host interactors (more than 50) and the 
numerous binding sites within the NS1 protein, which include for example binding sites for 
double-stranded RNA (15, 16), p85β for activation of phosphatidylinositol-3kinase (PI3K) 
signaling (17), RIG-I, which inhibits the induction of the type I IFN response (IFN-I) (18-20), 
and cleavage and polyadenylation specificity factor 4 (CPSF4; also known as CPSF30) (21). 
Among the NS1-interacting host proteins, CPSF4 is a component of the CPSF complex, which 
is involved in the last step of mRNA maturation and polyadenylation (22, 23). It has been 
demonstrated that IAV NS1 interacts with CPSF4, thus preventing CPSF4 binding to RNA and, 
consequently, inhibiting the 3′ end cleavage and polyadenylation of host pre-mRNA (21). It is 
assumed that this interaction contributes to the NS1-dependent regulation of several host genes 
and particularly to the inhibition of the IFN-response (24-27). Furthermore, it has been recently 
suggested that the CPSF complex could promote alternative splicing events. The CPSF complex 
can be recruited as a cofactor by known splicing regulators at sites distal to the polyadenylation 
site simultaneously to its usual mRNA binding sites (28-30). These data suggest that the 
interaction between NS1 and CPSF4 could also affect host gene expression at another level of 
regulation, such as host mRNA splicing.  
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The host tumor suppressor p53 is a master regulatory transcription factor that is activated in 
response to various cellular stresses and that regulates a broad range of biological processes, 
such as cell-cycle arrest, apoptosis and senescence (31, 32). An increasing number of reports 
suggest that p53 is also a key player in the regulation of immune, inflammatory and antiviral 
responses, including that of influenza viruses (33-42). Our current understanding is that the 
IAV-induced modulation of p53 endogenous expression, and subsequently of p53 
transcriptional activity, contributes to maintain a cellular state that favors viral replication 
during the time of infection (41, 43). We and others have indeed demonstrated that NS1 plays 
a major role in the functional interplay between IAV and the host p53 pathway (37, 42). We 
have shown that NS1 interacts with the endogenous p53 protein and alters the binding of p53 
to its responsive genes in a promoter-dependent manner (37). However, the complete 
mechanisms of NS1-induced modulation of p53 activity are still not fully understood. In 
addition to the canonical full-length p53 protein (also called TAp53  or p53α), the TP53 gene 
expresses about twelve p53 protein isoforms that result from combinational use of alternative 
promoters, splicing sites and/or translational initiation sites (44, 45). In particular, three 
Cterminal variants have been described ( ,  and ) that result from alternative splicing of 
TP53 intron 9 (TP53-i9). Exclusion of the entire intron 9 generates the canonical full-length 
p53 protein (or p53 ), whereas inclusion of alternative exons 9b and 9g contained in intron 9 
gives rise to p53  and p53  protein isoforms that present short residue sequence in place of the 
usual oligomerization domain present in p53 , resulting in shorter forms (47 kDa instead of 53 
kDa) (44, 45).  
The p53 isoforms have been shown to contribute to the cell-fate decision in response to stress 
but also to the maintenance of cell homeostasis, mainly by regulating transcriptional activity of 
the full-length p53  protein (44, 46, 47). We have notably demonstrated that increased 
expression of the C-terminal p53β and p53γ isoforms, resulting from fine control of the 
alternative splicing of TP53-i9, promotes G1 cell-cycle arrest and apoptosis in a p53 dependent 
manner (47). Interestingly, we reported that IAV differentially affect the endogenous expression 
of p53 isoforms at both transcriptional and post-transcriptional levels. In response to influenza 
infection, we observed an increased expression of the p53  isoform, known to be generated by 
partial retention of TP53-i9 (46). Reciprocally, modulations of endogenous expression of p53 
isoforms affect viral replication in a p53 -dependent manner  
(38).  
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Here, we further characterized the functional connections between IAV and the host p53 
pathway at the level of C-terminal spliced p53 isoforms. Using a minigene construct, we 
demonstrated that TP53 splicing is strongly modulated during the time course of IAV infection. 
In addition, we characterized the viral protein NS1 and the host factor CPSF4 as major partners 
involved in the IAV-induced modulation of the TP53 alternative splicing that was associated 
with a strong modulation of p53 transcriptional activity. Our study highlights for the first time 
a role for a cell factor, CPSF4, in TP53 alternative splicing in response to viral infection, and 
we have identified a novel regulator of TP53 alternative splicing in basal conditions. In the 
context of IAV infection, our results suggest that not only spliced p53β and p53γ isoforms, but 
also CPSF4, may contribute to the p53-mediated antiviral type I IFN response.       
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Results  
  
Influenza viral infection and NS1 protein modulates the alternative splicing of TP53-i9.  
To investigate the impact of infection on the alternative splicing of TP53-i9, we used a 
previously described minigene approach (38). This TP53-i9 minigene mimics alternative 
splicing of TP53-i9 and allows the analysis of the exclusion and/or partial retention of intron 9, 
which leads to the production of C-terminal ,  or  variants, respectively (Fig. 1A). H1299 
p53-null cells were transfected with TP53-i9 minigene plasmids for 36 hours then infected with 
two IAV strains (A/Puerto Rico/8/34 (H1N1) or A/Moscow/10/99 (H3N2)) at a multiplicity of 
infection (MOI) of 4 or 0.1 for 8 or 24 hours post-infection (hpi), respectively. IAV infection 
was validated by monitoring expression of NP and NS1 proteins by western blot, reflecting only 
slight differences of viral kinetics (Fig. 1B). Relative spliced RNA levels of the exogenous , 
 and  isoforms of p53, reflecting the three C-terminal spliced variants, were then quantified 
by reverse transcription-qPCR (RT-qPCR). Both H1N1 and H3N2 infections affected the levels 
of ,  and  p53 isoforms compared with mock-infected cells (Fig. 1B). At 8 hpi (MOI of 4), 
we observed a significant increase of the p53γ isoform levels by 1.39 and 1.27-fold in cells 
infected by H1N1 and H3N2, respectively, compared with the mock infection. However, no 
significant change was observed for both the α and β isoforms. In the context of multiple viral 
cycles (that is, MOI of 0.1 and 24 hpi), we observed a broader effect of infection on retention 
of TP53-i9. In addition to a significant 1.44- and 1.36-fold increase in the level of the p53γ 
isoform for H1N1 and H3N2, respectively, the level of the β isoform was also significantly 
increased in IAV-infected cells compared with mock-infected cells (1.43- and 1.60-fold 
increase for H1N1 and H3N2, respectively) (Fig. 1B). By contrast, the level of the major α 
isoform remained unaffected by H3N2 infection or slightly decreased by H1N1 infection. These 
results suggest that IAV infection promotes the retention of TP53i9, leading to the generation 
of  and  variants of p53 and, thus, could explain the IAVinduced expression of the p53  
isoform previously described (38).   
As the multifunctional NS1 protein is known to affect the host splicing machinery, we then 
investigated whether NS1 could modulate, by itself, the retention of TP53-i9. The TP53-i9 
minigene plasmid was co-transfected with the wild-type (wt) NS1-expressing pCI plasmid 
(H3N2), which induces NS1 expression, as verified by western blot (Fig. 1C, bottom panel). 
RT-qPCR analyses revealed that NS1 affected retention of TP53-i9. Indeed, NS1 expression 
was associated with a significant increase of both p53β and γ isoform levels compared with the 
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empty-plasmid transfection condition, the mean fold increases reaching 3.40 and 2.24, 
respectively (Fig. 1C, top panel). Similar to that observed in the above context of IAV infection, 
the level of p53α isoforms remained unaffected by transient NS1 expression. As the β and γ 
variants are known to be expressed at lower levels than the major α variant in basal conditions 
(36), we also determined the percentage of the combined β and γ (β+γ) isoforms out of the three 
C-terminal p53 isoforms to determine the relative proportion of intron 9 retention. NS1 
expression induced a significant >2-fold increase of the β+γ isoform proportion compared with 
the empty-plasmid condition (14.42 % versus 6.06 %, respectively, Fig. 1C, bottom panel). 
Overall, these results indicate that IAV infection, and also NS1 alone, can modulate the 
alternative splicing of TP53-i9, and favors the generation of β and γ isoforms of p53.   
  
The CPSF4-binding domain of NS1 is critical to NS1-mediated modulation of TP53-i9 
retention.  
The impact of different previously described NS1 mutants (16, 17, 21) on TP53-i9 retention 
was assessed using a TP53-i9 minigene in H1299 p53-null cells to determine the mechanisms 
underlying NS1-induced retention of TP53-i9. Three pCI plasmids were used to express  
H3N2 NS1 mutants that are deficient in their binding with either the PI3K p85β subunit (NS1-
Y89F), RNA (NS1-R38A/K41A) or CPSF4 (NS1-CPSF4b), all of which had detectable amount 
of the various NS1 proteins (Fig. 1D). Similar to wt NS1, there was a strong and significant 2-
fold increase in the proportion of β+γ isoforms in NS1-Y89F or NS1R38A/K41A mutants 
expressing cells, compared with the empty-plasmid condition, (13.03 and 12.58 % versus 5%, 
respectively) (Fig. 1D and Supplementary Fig. 1A). These results suggest that both RNA-
binding and p85β-binding domains of NS1 are not involved in the NS1-induced retention of 
TP53-i9. By contrast, the increased +  proportion observed in response to wt NS1 expression 
is abrogated when the NS1-CPSF4b mutant was expressed (Fig. 1D), which suggests that NS1 
mutants that could not bind to CPSF4 lost the capacity to induce TP53-i9 retention. Of note, the 
relative RNA levels of α, β and γ forms generated by the TP53-i9 minigene were significantly 
lower in NS1-CPSF4b expressing cells compared with the empty-plasmid condition, indicating 
an addition layer of regulation  (Supplementary Fig. 1A).   
Increasing numbers of wt NS1 and NS1-CPSF4b-expressing plasmids were then cotransfected 
with TP53-i9 minigene in H1299 cells. In the wt NS1 condition, no dosedependent effect was 
observed, and even minimal quantities of wt NS1 plasmid — resulting in a barely detectable 
protein levels — were sufficient to significantly increase the exogenous +  isoform proportion 
(Fig 1E and Supplementary Fig. 1B). By contrast, the generation of α,  and  forms from 
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the TP53-i9 minigene was progressively reduced with the NS1-CPSF4b mutant as the 
introduced plasmid quantity increased (Supplementary Fig. 1B). The augmentation of the +  
isoform proportion was abrogated at each NS1-CPSF4b dose used, which suggests that the 
CPSF4-binding domain of NS1 has a role in regulating TP53-i9 retention (Fig. 1E). At 
endogenous levels in A549 cells expressing the wt TP53 gene, we observed concordant patterns 
of p53β protein augmentation with wt NS1 versus its absence with NS1-CPSF4b, at least when 
low amounts of plasmid were transfected (Supplementary Fig.1D), in accordance with 
previous results (38). Altogether, these results suggest that the CPSF4-binding domain of NS1 
is critical for the NS1-induced retention of TP53-i9.  
  
  
IAV-mediated regulation of p53 expression is affected in NS1 CPSF4-mutant influenza 
virus.  
We then investigated the impact of NS1-CPSF4b on the expression of spliced p53 isoforms in 
the context of IAV infection. The NS1-CPSF4b mutant virus was previously described as 
having strongly attenuated replication (48). To minimize this limitation, we used the reverse 
genetic system of the highly replicative A/PuertoRico/8/33 virus (H1N1, PR8) (49) to produce 
viruses expressing the wt NS1 or mutant NS1-CPSF4b proteins. Virus recovery from pHW2000 
plasmid transfection was achieved, and recombinant PR8/NS1-wt and PR8/NS1CPSF4b 
viruses were generated and titrated. These two viruses presented comparable growth kinetics 
and infectivity (Fig. 2A). A549 cells (p53 wt) were infected with either virus, and endogenous 
mRNA relative levels of p53 isoforms were measured by RT-qPCR and western blot. At 8 hpi, 
the PR8/NS1-wt virus induced a significant 25% reduction of endogenous p53 total mRNA 
levels compared with mock infection, and a slight but not significant increase in both p53  
isoform mRNA and protein levels (Fig. 2B, C). Thus, infection with PR8/NS1-wt virus 
reproduced what was observed with endogenous p53 isoform at mRNA and protein levels (38) 
and in H1299 NS1-transfected cells (Fig. 1C). In contrast to PR8/NS1-wt virus, no variation of 
total p53 mRNA levels was observed with PR8/NS1-CPSF4b virus at 8 hpi compared with 
mock infection, while a significant 1.65-fold up-regulation of β mRNA variants and a slight 
increase of p53β protein levels was detected, suggesting that the CPSF4binding domain of NS1 
has a role in modulating p53 isoform expression (Fig. 2B,C). At 24 hpi, no changes were 
observed at mRNA levels in the PR8/NS1-wt virus-infected cells, whereas a drastic and 
significant increase of β mRNA variants was induced by PR8/NS1CPSF4b infection compared 
with mock infection (Fig. 2D). However, this increase of mRNA levels was not matched by a 
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similar increase in p53β protein levels, as observed by western blot (Fig. 2E). This discrepancy 
can result from other regulations occurring during the several viral cycles taking place through 
the time course of 24 hpi. Nevertheless, these data showed that endogenous p53 isoforms 
expression is differentially affected by influenza virus expressing either the wt NS1 or NS1-
CPSF4b mutant protein, underlying the critical role of the CPSF4 binding domain in NS1-
induced modulation of p53 isoform expression.   
Interestingly, we observed that CPSF4 itself affects spliced p53 isoforms expression in basal 
conditions. In fact, we observed a slight increase of α variant mRNA in conjunction with a 
significant 40% reduction of  variant mRNA levels in p53-null H1299 cells, previously 
transfected with the TP53-i9 minigene plasmid, when treated with a pool of small interfering 
RNA that targeted CPSF4 (si-CPSF4), in comparison with a non-specific si-RNA (si-ctrl) 
(Supplementary Fig. 2A). In accordance, a similar observation was made at endogenous levels 
in si-CPSF4-treated A549 cells with an increase in total p53 mRNA levels but no change in the 
proportion of β variant mRNA levels when compared with si-ctrl treated cells (Supplementary 
Fig. 2B). Thus, these results suggest that the silencing of the cellular CPSF4 factor contributes 
to the exclusion of TP53-i9, which modulates the spliced p53 isoforms ratio and favors the 
increase of p53  variant mRNA levels — the major form expressed by the TP53 gene. 
Altogether, these results demonstrated that CPSF4-binding domain of NS1 is critical for the 
IAV-mediated regulation of p53 isoforms expression. Moreover, it suggests a role of the NS1 
interactant, CPSF4, in p53 isoform expression in both mock and infected conditions.  
  
CPSF4, NS1 and the CPSF4-binding domain of NS1 protein play a critical role in p53 
transcriptional activity.  
As we observed that silencing of CPSF4 modulates p53 isoforms expression patterns in basal 
conditions, we investigated the effect of CPSF4 silencing on p53 transcriptional activity in non-
infected cells. We used a panel of luciferase reporter vectors that reflect either the intrinsic p53 
transcriptional activity (pG13-Luc, a de novo generated promoter containing 13 consecutive 
p53 responsive elements) or promoter activity of well-characterized p53 target genes (MDM2-
Luc, p21-Luc or Bax-Luc). Compared with si-ctrl, si-CPSF4 treatment increased pGL13-Luc 
luciferase activity, indicating that CPSF4 modulates p53 transcriptional activity 
(Supplementary Fig. 2C). These results support that CPSF4 contributes to modulate the 
transcriptional activity of p53 in a promoter-dependent manner.  
We then investigated whether the NS1-mediated modulation of p53 isoforms expression pattern 
affected p53 transcriptional activity and whether such modulation was dependent on the CPSF4-
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binding domain of NS1 (Fig. 3). Increasing amounts of wt NS1- or NS1-CPSF4expressing 
vectors were co-transfected with either a pG13-Luc, MDM2-Luc, p21-Luc or BaxLuc luciferase 
reporter vector in A549 cells (NS1 expression was verified by western blot in Supplementary 
Fig. 1C). In wt H3N2 NS1 transfected cells, we observed a slight decrease of the pG13-Luc 
luciferase activity together with significant increase of Bax and reduction of MDM2 and p21 
promoter activities compared with the empty-plasmid condition, which suggests that NS1 
modulates p53 transcriptional activity (Fig. 3), in accordance with previously published studies 
(including ours), demonstrating that NS1 modulates p53 transcriptional activity in a promoter-
specific manner (37, 42). In cells expressing the NS1CPSF4b mutant, pG13-Luc luciferase 
activity was significantly increased compared with the control and wt NS1 conditions, resulting 
in dose-dependent increase of relative luciferase activity reaching a maximum of 6-fold 
induction. This was supported by the observations that NS1-CPSF4b mutant differentially 
affected MDM2-Luc, p21-Luc and Bax-Luc promoter activities compared with wt NS1 (Fig 3). 
These results indicate that the CPFS4-binding domain of NS1 plays a critical role in the 
regulation of p53 transcriptional activity.   
Altogether, these data indicate that the CPSF4-binding domain of NS1, and CPSF4 itself, affects 
p53 transcriptional activity and p53-responsive promoters. In addition, the modulation of p53 
isoform expression pattern, resulting from alternative splicing of TP53-i9 and induced by NS1 
through its CPSF4-binding domain or by CPSF4 itself, was paralleled with modulation of p53 
transcriptional activity, suggesting a functional impact on viral replication.   
  
The silencing of spliced p53 isoforms impairs IAV replication.  
To support the hypothesis of an interplay between NS1, CPSF4 and p53 activity and its 
functional impact on viral replication, we first determined whether a combined endogenous 
silencing of the TP53-i9 alternatively spliced p53β and γ isoforms could affect IAV replication. 
We treated A549 cells with either a si-ctrl or a siRNA that targets alternatively spliced TP53-i9 
(si-P53i9) prior infection with H3N2 influenza virus (Fig. 4A). First, we verified the silencing 
of spliced p53 isoforms in response to si-P53i9 treatment (Fig. 4C-D). In non-infected cells, si-
P53i9 treatment decreased both  mRNA variant and p53  protein levels by about 40%. As 
previously described (28), infection alone (si-ctrl condition) did not affect endogenous p53 total 
mRNA levels but induced a significant and strong increase in endogenous β mRNA variant 
levels at 72 hpi (a 4.23- and 6.80-fold increase compared with mock infections for MOIs of 0.1 
and 0.01, respectively) (Fig. 4C). Such induction was abrogated in si-P53i9-treated cells, 
demonstrating the si-RNA treatment efficacy along the infection time-course. Second, we 
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analyzed IAV cell titers in these conditions (Fig. 4B). Silencing of TP53-i9 spliced p53 isoforms 
was associated with a significant decrease in viral titers, particularly at 48 hpi with a 6.5- and 
19-fold decreased production of influenza virus (for MOIs of 0.1 and 0.01, respectively) 
compared with si-ctrl treatment. Accordingly, viral expression of NP and NS1 proteins 
decreased in si-P53i9-treated cells compared with si-ctrl at 72 hpi, suggesting that spliced p53 
isoforms have pro-viral activity (Fig. 4D). These data are in accordance with our previously 
published study, which highlighted p53β as a pro-viral factor (38).  
Interestingly, levels of p53α protein were reduced in IAV-infected cells compared with 
mockinfected cells (si-ctrl condition) at both 48 and 72 hpi (Fig. 4D). Surprisingly, while si-
P53i9 treatment did not change the level of p53α protein in mock-infected cells, we clearly 
observed more p53α in infected cells and si-P53i9-treated A549 cells compared with si-ctrl-
treated cells. As these variations at the protein level were not observed at the mRNA level, these 
observations suggest that C-terminal spliced p53 isoforms contribute to the IAV-reduction of 
p53  regulation through a post-transcriptional mechanism (Fig. 4D).   
As CPSF4 affects the spliced p53 isoform expression pattern and p53 transcriptional activity 
(Supplementary Fig. 2) and as the CPSF4 promoter contains p53-response elements (data not 
shown), we analyzed CPSF4 expression in si-P53i9-treated conditions. Interestingly, silencing 
of the spliced β and γ mRNA variants was associated with an increase in CPSF4 protein, both 
in non-infected and infected conditions, while it decreased CPSF4 mRNA levels, suggesting 
there is a regulation of CPSF4 at the transcriptional level and that the CPSF4 protein 
stabilization in IAV-infected cells is dependent upon spliced p53 isoforms (Fig. 4D and 
Supplementary Fig. 3). These data suggest a regulatory loop between CPSF4 and p53 isoforms 
that could modulate IAV infection.  
  
Silencing of CPSF4 also impacts the IAV replication.  
Owing to the multilayer interplay between p53 isoforms and CPSF4, as well as between NS1 
and CPSF4, we investigated the impact of cellular CPSF4 silencing on IAV replication. First, 
we compared IAV growth kinetics in A549 cells treated with si-CPSF4 or si-ctrl (Fig. 5A). 
When CPSF4 expression was drastically reduced by si-CPSF4 treatment, at mRNA and protein 
levels (Fig 5B, C), a significant increase of viral replication was observed compared with si-
ctrl cells, with viral titers increased by up to 7 times at 72 hpi (MOI of 0.01) (Fig. 5A). 
Accordingly, viral expression of NP and NS1 proteins were increased in si-CPSF4-treated cells 
compared with si-ctrl-treated cells (Fig. 5B). These data suggest that CPSF4 exhibits an anti-
viral effect in an independent manner. Inversely, influenza virus (si-ctrl condition) decreased 
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CPSF4 protein expression in A549 cells while it increased CPSF4 mRNA levels, suggesting 
there is a regulation of CPSF4 at post-transcriptional levels in response to infection (Fig. 4D 
and Supplementary Fig. 3). Moreover, as expected regarding our previous results, si-CPSF4 
treatment altered endogenous p53 expression by enhancing levels of both p53α and p53β 
proteins at 72 hpi (Fig. 5B).   
Second, we measured IAV growth kinetics in H1299 p53-null cells treated with si-CPSF4 or si-
ctrl (Fig. 5D). In clear contrast with results obtained in A549 cells, the si-CPSF4 treatment had 
no significant impact on viral growth and very limited impact on viral expression (Fig. 5E). 
Interestingly, the increased CPSF4 mRNA levels seen in response to infection in A549 cells 
(Fig. 5C) was inhibited in absence of endogenous p53 expression (si-ctrl conditions) (Fig. 5F). 
However, at the protein level, CPSF4 protein expression remained elevated in p53null cells in 
both non-infected and infected cells, suggesting that CPSF4 protein stability is dependent upon 
p53 (Fig. 5E). These results support a regulatory loop between CPSF4 and p53 during IAV 
infection and suggest that the CPSF4 anti-viral effect on IAV replication is p53- dependent.  
  
TP53 spliced p53β and p53γ isoforms together with CPSF4 contribute to a p53-mediated 
type I IFN-response to IAV infection and extracellular stresses.  
Given that p53 is a key player in the regulation of innate immune responses (reviewed in (33)), 
and that the CPSF4-binding domain of NS1 has been recently associated with the type I IFN 
regulation mechanism during infection (50), we wanted to further investigate the role of TP53 
gene pathway, as well as that of CPSF4, on type I IFN responses in the context of infection, 
using a siRNA-based approach (Fig. 6). A549 cells were transfected with either a pool of siRNA 
targeting all p53 isoforms (si-P53tot) (Fig. 4A), siRNA targeting spliced p53β and p53γ 
isoforms (si-P53i9), siRNA targeting CPSF4 (si-CPSF4) or a non-specific siRNA (sictrl). 
Treated cells were then infected with influenza virus H3N2 at a MOI of 4. Supernatants were 
harvested at 24 hpi to monitor IFNα and IFNβ levels (Fig. 6A), while the siRNA efficiency was 
controlled by western blot on cell lysates (Fig. 6C).  
First, our results indicated that the knockdown of all p53 isoforms (including full-length p53α) 
strongly reduced the production of IFN-I compared with cells treated with si-ctrl, with more 
than a 50% and 40% reduction of IFNα and IFNβ, respectively (Fig. 6A). This result concurred 
with previous reports and underlined the contribution of TP53 to the regulation of IFN mediated 
antiviral response (51). Interestingly, we observed a very similar impact on IFN production in 
the si-P53i9-treated condition, with around 50% reduction of IFNα and IFNβ (Fig. 6A). More 
importantly, since the reduction of IFN was similar using either si-P53tot or si-P53i9, it 
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suggested that the spliced  and  mRNA variants are the major, if not the only, component of 
the global p53-mediated regulation of the IFN response. Regarding CPFS4, a significant 50% 
reduction of IFN  and IFN  was observed in si-CPSF4-treated cells compared with si-ctrl-
treated cells, suggesting that CPSF4 is also an important player, by itself, in the regulation of 
IFN-I production. Furthermore, the combination of si-P53i9 and siCPSF4 treatments also 
decreased the level of IFN production; however, the reduction of IFN was in a range similar to 
that seen with single siRNA treatments, without any cumulative effect. These observations were 
also supported by western blot, using the phosphorylation of signal transducer and activator of 
transcription 1 (STAT1) as an indicator of IFN response (Fig. 6C). These data suggest that both 
the spliced p53β and p53γ isoforms and CPSF4 are involved in promotion of IFN-I production 
in response to IAV infection, certainly through a common pathway.  
To determine whether the CPSF4- and spliced p53 isoform-induced IFN production also occurs 
in an extracellular stress context, distinct from IAV infection, we performed similar experiments 
whereby we measured the response of siRNA-treated cells exposed to poly(I:C) treatment, 
which mimics non-specific viral signaling through Toll-like receptor 3 (TLR3) (Fig. 6B, D). 
Interestingly, we obtained similar results to that seen with IAV infection using the range of 
siRNA-treatment, but only in the context of IFNα. Indeed, compared with si-ctrltreated cells, 
only a limited but statistically significant reduction of IFNβ was achieved in siP53tot-treated 
cells (Fig. 6B). These data suggest that both CPSF4- and spliced p53 isoformsinduced IFN 
production is specifically dependent upon IAV infection.  
Altogether, these results clearly indicate that spliced p53β and p53γ isoforms are major 
contributor to the global p53-mediated regulation of type I IFN. Interestingly, our data suggest 
that CPSF4/spliced p53 isoforms are part of the same pathway, stimulating type I IFN 
production during IAV infection.   
Discussion   
  
During their replication cycle, IAV are known to “hijack” the host splicing machinery to process 
their smallest gene segments (M and NS). To do this, they have developed accurate regulation 
mechanisms to appropriate the host spliceosome to enable the expression of specific spliced 
IAV products throughout infection (5). Indeed, several genome-wide screening studies, 
dedicated to pinpointing important host factors for IAV replication, have highlighted a large 
number of cellular proteins involved in RNA maturation and splicing processes, including 
several splicing factors (5, 52-54). However, the impact of IAV infection on the regulation of 
splicing of host mRNA has not yet been extensively investigated.  
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The transcription factor p53, also named “guardian of the genome” or “cellular gatekeeper”, is 
most of the time – if not always – targeted by viruses during the time-course of infection (34, 
55). This feature is a powerful way for viruses to modulate or hijack p53-mediated cellular 
functions, including those involved in the regulation of the immune and inflammatory responses 
(33, 39). In the context of IAV, we and others have demonstrated that IAV target p53 at several 
transcriptional and post-transcriptional regulatory levels (36-38, 40-42). Among these, we 
demonstrated a functional interplay between IAV viral production and p53 isoforms, notably 
the p53  isoform, known to be generated by partial retention of TP53-i9 (38, 56). Here, we 
describe another layer of interplay, showing that IAV infection modulates the alternative 
splicing of TP53 at the level in intron 9, in favor of under-represented spliced forms such as 
p53 , which concurs with that previously observed (38). Interestingly, the nonstructural protein 
NS1 appears to be a major player in this mechanism, as experiments involving transient NS1 
expression recapitulated our initial observation on TP53 splicing in the context of infection 
(Fig. 1C). Among the multiple functions of NS1, we currently know that NS1 interferes with 
several cellular signaling pathways, including p53, but also has an important role in the 
modulation of mRNA maturation and splicing (6, 7), and our results illustrate well how these 
different functions overlap during infection.  
One striking result in our study was that the CPSF4-binding domain of NS1 is involved in the 
NS1-mediated modulation of TP53-i9 retention, as demonstrated by transient expression 
experiments (Fig. 1 and 4) and the use of NS1 recombinant viruses (Fig. 2). In addition, our 
results suggest a regulatory loop between IAV NS1, and host factors CPSF4/p53 during IAV 
infection (Fig. 5-7). Interestingly, a large part of literature dedicated to CPSF4, originates from 
studies performed in the context of IAV infection (21). The first described role of CPSF4 is to 
participate to maturation and polyadenylation of cellular pre-mRNA. The binding of NS1 to 
CPSF4 inhibited these activities, contributing to the NS1-mediated regulation of host gene 
expression and inhibition of the type I IFN response (24, 25, 27, 57). In line with these features, 
our results indicate that CPSF4 contributes to the p53-mediated type I IFN response to IAV 
infection (Fig. 6), supporting the hypothesis of a link between CPSF4 and the innate immune 
response. More recently, several reports have investigated the functional contribution of CPSF4 
to the spliceosome machinery, acting as a cofactor for splicing regulators, such as RBFOX2 or 
HNRNPA1, suggesting that CPSF4 is more directly involved in the regulation of alternative 
splicing (28-30). Once again, our results are in good agreement with this emerging role for 
CPSF4. Indeed, we demonstrated that CPSF4 is involved in the regulation of TP53 splicing, 
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showing that the use of a specific si-RNA targeting CPSF4 contributes to the exclusion of TP53-
i9 in favor of the expression of p53α variant, even in basal conditions, outside of an IAV 
infection context (Supplementary Fig. 2). Thus, we identified a novel splicing regulator of the 
TP53 alternative splicing at the level of its intron 9. Future investigations will be necessary to 
understand whether this CPSF4-mediated modulation of splicing is specific to TP53 (or to a 
subset of host genes) or rather results from a more global impact on host splicing.  
Altogether, our combination of different experimental approaches revealed strong regulatory 
connections between NS1, CPSF4 and p53. To make a complete picture of this virus–host trio, 
we focused on TP53 splicing and p53 transcriptional activity. First, we demonstrated that 
CPSF4 modulates both TP53 splicing and p53 transcriptional activity (Supplementary Fig. 2). 
These two events are likely directly correlated, as we previously demonstrated that p53 spliced 
isoforms regulate p53 transcriptional activity (45, 46). In parallel, we also demonstrated that 
NS1 modulates the alternative splicing of TP53-i9, in favor of p53β and p53γ isoforms, and that 
the CPSF4 binding domain of NS1 was involved in this modulation (Fig. 1). This NS1-mediated 
modulation of TP53 splicing was correlated with a modulation of p53 transcriptional activity, 
the latter being in agreement with previously published works (37, 42). In addition, several 
studies, including ours, performed in different physiological and pathological contexts, clearly 
indicate that alteration or disruption of the splicing machinery have a marked effect on p53 
transcriptional activity and p53-mediated cellular responses in a promoter-dependent manner, 
suggesting a role for p53 spliced isoforms in these processes (47, 58). Our results obtained in 
the case of IAV infection, or in the experimental contexts of  
NS1 transient expression/silencing of CPSF4, confirmed these observations, as we described a 
marked deregulation of TP53 splicing associated to a modulation of p53 transcriptional activity 
in a promoter dependent-manner (Figs. 1-3).  
Finally, our results focused on viral production and p53-mediated regulation of IFN-I to 
complete our understanding of the underlying biological significance of the NS1/CPSF4/p53 
interplay. Using specific si-RNAs, we first demonstrated that p53β and p53γ isoforms have a 
pro-viral effect (Fig. 4), in line with our previous study (38). In parallel, we have also observed 
that silencing of CPSF4, which modulates TP53 splicing, significantly affects viral production 
in a p53-dependent manner (Fig. 5). This latter experimental silencing of CPSF4 is comparable 
to the early stages of IAV infection, in which NS1 hampers CPSF4 functions. We hypothesize 
that the role of CPFS4 in IAV infection may not only rely on the maturation of host pre-mRNA 
(21-23) but also on the modulation of TP53 splicing and p53-mediated responses by NS1. 
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Indeed, little is known about the impact of NS1 on the CPSF complex at the level of splicing 
regulation. Our hypothesis is that NS1, via its binding with CPSF4, alters the CPSF complex 
and consecutively modify its recruitment as cofactor for splicing regulators. In addition, a 
converging point between known functions of CPSF4 and those of p53 is the regulation of IFN-
I responses. Indeed, CPSF4 is involved in the NS1-dependent regulation of several host genes 
and particularly to the inhibition of the IFN-I response (2427). In addition, p53 is known to 
constitute an amplification loop in the innate immune response, TP53 being part of the family 
of IFN-stimulated genes (ISGs), and p53 regulates the expression of several genes involved in 
IFN-I response (reviewed in (33)). Our results confirmed these observations (Fig. 6) and 
suggested that spliced p53β and p53γ isoforms are major contributor to the global p53-mediated 
regulation of type I IFN, and that CPSF4 might be involved in the same regulatory loop.   
On the basis of our results, we can propose the following model (depicted in Fig. 7). During 
IAV infection, NS1 inhibits p53 transcriptional activity via its interaction with p53, but also via 
the modulation of TP53 splicing by “buffering” the function of CPSF4 in mRNA maturation 
and splicing (Fig. 7). As a consequence, the spliced p53 isoform modulation of p53 
transcriptional activity, and notably p53-mediated antiviral responses, coupled to the cellular 
impact of CPSF4 blockade, positively influence viral production. When NS1 is mutated, 
preventing its binding to CPSF4, this regulation loop is impaired, and the antiviral response is 
increased, limiting viral production (Fig. 7). In future studies, it will be interesting to investigate 
the presence of naturally occurring mutations in NS1 of IAV circulating strains that could 
interfere in this NS1/CPSF4/p53 trio, to evaluate a possible impact on strain pathogenesis and 
virulence.  
In conclusion, our results have aided understanding of the complex mechanisms IAV hijacking 
of the host p53 pathway during infection, but they have also highlighted a particular virus–host 
trio NS1/CPSF4/p53 that is crucial for viral replication via mRNA maturation and splicing and 
p53-mediated antiviral responses.   
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Methods  
  
Cells lines, influenza viruses and infection  
Human lung epithelial A549 (wild-type p53; ATCC CCL-185) and H1299 (p53 null; ATCC  
CRL-5803) cells were maintained at 37°C in Dulbecco’s modified Eagle’s medium (DMEM; 
Life Technologies) supplemented with 10% (or 5% for H1299 cells) of heat-inactivated fetal 
calf serum (Dutscher), 2 mM L-glutamine (Sigma Aldrich), penicillin (100 U/mL) and 
streptomycin (100 μg/mL) (Lonza), under a 5% CO2 atmosphere.   
Influenza viruses A/Moscow/10/99 (H3N2) and A/Puerto Rico/8/34 (H1N1), obtained from the 
French national influenza monitoring network GROG (Groupes Régionaux d’Observation de la 
Grippe, Lyon, France), were produced in Madin-Darby canine kidney (MDCK) cells  
(ATCC CCL-34) in Eagle’s minimum essential medium (EMEM; Life Technologies). Viruses 
were titrated on confluent layers of MDCK cells in 96-well plates to determine the 50% tissue 
culture infectious dose by endpoint titration (TCID50/mL), which was determined using the 
Reed and Muench statistical method (59). A549 and H1299 cells were infected at a multiplicity 
of infection (MOI) of 0.1 or 4 TCID50/cell. After 1 h of viral adsorption, cells were overlaid 
with DMEM supplemented of 2 mM L-glutamine, penicillin (100 U/mL), streptomycin 
(100 μg/mL) and 0.5 μg/mL TPCK-trypsin (Roche diagnostics) and incubated at 37°C.   
For viral growth kinetic assays, MDCK cells were infected at MOI of 10-1 or 10-2 TCID50/cell. 
After a 1 h viral adsorption period, cells were overlaid with Eagle's minimum elementary 
medium (EMEM, Lonza) supplemented with 1 μg/ml trypsin (Roche diagnostics) and further 
incubated at 34 °C. Harvested supernatants were centrifuged at 1500g for 10 min and stored at 
− 80 °C until analysis.  
  
Plasmids and TP53-i9 minigene  
For transient expression of NS1, A549 and H1299 cells at 40% of confluence were transfected 
using TransIT-LT1 Reagent (Mirus), following manufacturer’s instructions, with a panel of pCI 
plasmids empty or carrying wild-type or mutated NS1 sequences derived from the H3N2 strain. 
Wild-type pCI-NS1 (NS1 wt) was a kind gift from Dr Nadia Naffakh, Institut Pasteur, France. 
Three pCI-NS1 mutants (NS1-Y89F, NS1-R38A/K41A and NS1-CPSF4b, mutated from amino 
acids 184 to 188, sequence RFLRY in place of GLEWN) were obtained by sitedirected 
mutagenesis. Each plasmid was validated by sequencing.   
For the TP53 splicing assay, the pcDNA3-ASAi9 p53 minigene plasmid (named TP53-i9 
minigene) was used, the design and protocol of which were previously described (47). The 
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pcDNA3-ASAi9 p53 minigene contains a portion of the TP53 gene that includes the 3′ end of 
exon 9, the entire intron 9 and the beginning of exon 10, as pictured in Fig. 1A, as well as the 
neomycin-resistant gene used to assess transfection efficiency. In infection experiments, cells 
were infected as described, 24-48 h after TP53-i9 minigene transfection. In co-transfection 
experiments, the TP53-i9 minigene was transfected simultaneously with indicated quantities of 
the pCI-NS1 wt-expressing plasmid.   
  
RNA analysis and real-time quantitative PCR   
Cells lysates were harvested at 8 hours post-infection (hpi; MOI of 4) or at 24 hpi (MOI of 0.1) 
and total RNA was extracted using the RNeasy minikit (Qiagen), according to supplier protocol. 
Reverse transcription was performed on 1µg of total RNA with SuperScriptII Reverse 
Transcriptase (Invitrogen) at 42°C followed by a quantitative PCR using SYBR Green qPCR 
Master Mix (Agilent, Santa Clara, CA, USA). In the TP53-i9 minigene experiment, specific 
primers for each p53 spliced RNA or neomycin-resistance gene were used, as previously 
described (47). For quantitation of endogenous p53 mRNA levels, qPCR was carried out using 
TaqMan 2X Universal PCR Master Mix No AmpErase UNG (Applied Biosystem, Carlsbad, 
CA, USA) with specific sets of primers and probes: E8/9 primers for amplification of total p53 
isoforms, p53β primers for amplification of β forms and Actin primers for normalization, as 
previously described (47). The use of actin as a normalisation control was validated in control 
experiments, indicating that IAV infection and/or si-CPSF4 did not affect actin CT by RTqPCR. 
A complete list of primers and probes used in this study is available in Supplementary Table 
1. The ΔΔCT method was used to determine the fold change of mRNA levels using neomycin-
resistance or actin expression level as a reference. Relative mRNA levels were quantified in 
triplicate, in at least three independent experiments, to perform statistical analyses. The 
proportion of β+γ mRNA variants on total expression was measured dividing the sum of β and 
γ relative quantities, by the sum of α, β and γ quantities, all forms being individually normalized 
against neomycin. This proportion of β+γ variants is used an indicator of the extent of splicing 
for comparison purposes.  
  
Western blotting  
Total protein was extracted by scraping and syringing cells in 1X NuPAGE LDS buffer 
(Invitrogen). Approximately 15-30 μg of protein were loaded on 10 or 12% SDS gels and 
analyzed by immunoblotting using the following antibodies: sheep polyclonal antibody antitotal 
p53 isoforms (SAPU, Dundee, UK); rabbit polyclonal antibodies anti-NS1 (30F/31F, kind gift 
  { PAGE   \* MERGEFORMAT }  
of Daniel Marc, INRA Tours, France), anti-NP (CDC/IVPS, 30AUG01) and antiphosphorylated 
(Tyr701) STAT1 (#9167, Cell Signaling Technology); mouse monoclonal antibodies anti-p53 
TA isoforms (DO-1, Dundee, UK), anti-NS1 (SantaCruz, sc-130568), anti-CPSF4 antibody 
(Santa-Cruz sc-393316), anti-STAT1 (#9176, Cell Signaling Technology) and anti-Ku80 
(AbCam), which was used as loading control.   
  
Transactivation assay   
A549 cells were transfected with 1 μg of firefly luciferase reporter vectors corresponding to 
different p53-responsive elements. Cells were co-transfected with empty or NS1-expressing 
pCI plasmids and harvested at 48 hpi. Transfection efficiency was normalized using 100 ng of 
Renilla luciferase plasmid. Luciferase activity was measured in whole cell extracts, in triplicate 
in two independent experiments, using the Dual-Luciferase Reporter Assay System  
(Promega), according to the manufacturer’s instructions. The different reporter vectors used 
were pG13-Luc with the luciferase gene under the control of thirteen copies of the p53binding 
consensus sequence (5′- CCAGGCAAGTCCAGGCAGG- 3′) and p21-Luc, Mdm2Luc and 
Bax-Luc with the luciferase gene under the control of the complete (p21) or partial (Mdm2 and 
Bax) promoter sequence of the corresponding genes (60-62).   
  
Recombinant viruses  
Recombinant PR8/NS1 wt and PR8/NS1-CPSF4b viruses were generated by reverse genetics 
approaches, as previously described (63). Briefly, a pHW2000 plasmid containing NS sequence 
from H3N2 (49) was mutated to generate a NS1-CPSF4b mutant (from amino acid 184 to 188, 
sequence RFLRY in place of GLEWN). Recombinant virus generation was performed by 
transfection of 293T cells (ATCC CRL-3216) using set of pHW2000 plasmids from PR8 system 
and pHW2000 plasmid containing NS wt or NS1-CPSF4b sequences from H3N2 coding. At 48 
hpi, viruses in the culture supernatant were harvested and used to infect a layer of MDCK cells. 
Viral stocks were prepared after three passages on MDCK cells, and titers were measured using 
standard TCID50 methods. Full genomes of recombinant viruses were validated by sequencing.   
  
si-RNA treatment  
A549 or H1299 cells (cell confluence, 50%), seeded in antibiotic-free medium, were transfected 
twice at 24 h intervals with either 50 nM of nonspecific si-RNA (si-ctrl, catalog number 0R-
0030-Neg05; Eurogentec), or a pool of si-RNA CPSF4 (on-Target plus Human CPSF4 #10898 
siRNA smartpool, Dharmacon), specific si-RNAs targeting global p53 isoforms (si-P53tot) or 
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spliced p53β and p53γ isoforms (siP53-i9, Fig. 5A; Eurogentec based on sequences in (47)), 
using Oligofectamine (Life Technologies) according to the manufacturer’s instructions. Cells 
were then infected or treated 24 h after the last si-RNA transfection. The efficiency of si-RNA 
mediated knockdown after treatment was evaluated by RT-qPCR and/or western blotting.  
  
IFN-α/β ELISA  
Twenty-four hours after si-RNAs transfection, A549 cells were infected with H3N2 at MOI of 
4 or alternatively treated with 50 μg/mL of extracellular poly (I:C) (Sigma Aldrich). Fortyeight 
hours after transfection, IFN-α and IFN-β levels were quantified in supernatants using the 
VeriKine Human Interferon Alpha Multi-Subtype Serum ELISA Kit or the VeriKineHSTM 
Human Interferon Beta Serum ELISA kit (PBL Assay Science, NJ, USA),  
respectively, following the manufacturer’s protocol.  
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Figures captions  
  
Figure 1 – Influenza viruses and the viral NS1 protein alone modulate TP53-i9 minigene 
alternative splicing. (A) Schematic of the TP53-i9 minigene. Intron 9 of p53 was inserted into 
pCDNA3 plasmids with part of exon 9 and 10 on both sides, transcription of mRNA 
corresponding to each spliced variants was under control of the CMV promoter (47). (B) Levels 
of mRNA corresponding to p53 spliced variants α, β and γ were measured in H1299 cells (p53 
null) in which the TP53-i9 minigene plasmid was transfected 36 hours before mock infection 
or infections by H1N1 or H3N2 influenza viruses. Cells lysates were harvested at 8 hpi for 
infection at MOI of 4 or at 24 hpi for infection at MOI of 0.1, and relative levels of mRNA 
corresponding to α, β and γ p53 spliced variants were measured by specific RT-qPCR. mRNA 
level of each variant was normalized against the neomycin-resistance gene, which is also 
encoded by the TP53-i9 minigene. Viral protein expression (NP and NS1) was monitored by 
western blot. (C) The relative spliced mRNA level of p53α, p53β and p53γ isoforms was 
measured in H1299 cells 48 h after co-transfection of TP53-i9 minigene and 1µg of an empty 
pCI plasmid or a plasmid containing wt NS1 (pCI NS1 wt, from influenza strain 
A/Moscow/10/99 (H3N2)) and was used to calculate the proportion of β+γ isoforms out of the 
total α, β and γ variant p53 mRNA expression. Mean values +/- standard deviation for at least 
three independent experiments are shown, and statistical tests compared each condition with its 
control condition using two-way ANOVA (**, p < 0.01; ***, p < 0.001). (D, E) In H1299 cells, 
the TP53-i9 minigene was co-transfected with 1µg of empty pCI, pCI NS1wt (results extracted 
from Figure 1C) or pCI NS1-Y89F, pCI NS1-R38A/K41A and pCI NS1-CPSF4b mutants (D) 
or with increasing amounts (0.1, 0.5 or 1µg) of pCI NS1 wt or pCI NS1-CPSF4b plasmid (E). 
Forty-eight hours after co-transfection, levels of α, β and γ variant mRNA were measured 
(Supplementary figure 1) and used to estimate the β+γ proportion. Efficacy of NS1 transient 
expressions was validated by western blot. Mean values +/- standard deviation from more than 
three independent experiments are shown, and statistical tests compared each condition with its 
control empty condition or NS1 wt condition using Student’s t-test (*, p < 0,05; **, p < 0.01 
and ***, p < 0.001).  
  
Figure 2 – IAV-regulated p53 expression is affected by mutant NS1 CPSF4-binding 
mutant. A. Comparative viral kinetics between recombinant IAV PR8/NS1 wt or 
PR8/NS1CPSF4b viruses. A549 cells were infected with the two viruses at MOI of 0.01 and 
supernatants were harvested at 24, 48, 72 and 96hpi for determination of viral titers. B-E.  
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A549 cells were mock-infected or infected with either recombinant IAV PR8/NS1 wt or 
PR8/NS1-CPSF4b viruses. Cells lysates were harvested at 8 hpi (MOI of 4, B, C) or 24 hpi 
(MOI of 0.1, D, E). Detection of total p53 and p53β isoforms was performed by RT-qPCR and 
western blot (SAPU antibody). Viral proteins NP and NS1 were also detected. # and ## indicate 
short and long exposure, respectively. Mean values +/- standard deviation of experimental 
duplicates are shown and statistical tests compared each condition with its control condition 
using two-way ANOVA and Dunnett’s post-test (*, p < 0.05; **, p < 0.01 and ***, p < 0.001).  
  
Figure 3 – The CPSF4-binding domain of NS1 protein plays a crucial role in the alteration 
of p53 isoforms expression and p53 transcriptional activity. A549 cells were transfected 
with pG13-Luc, Mdm2-Luc, Bax-Luc or p21-Luc reporter plasmids together with increasing 
concentrations of an NS1 expressing plasmid (either H3N2 NS1 wt or H3N2 NS1CPSF4b 
mutant). p53 transactivation activity was measured after 48h, in triplicate on two independent 
experiments and expressed in relative luciferase units (RLU) compared with the empty plasmid 
condition. Mean values +/- standard deviation are shown and statistical tests compared each 
condition with the empty plasmid condition using one-way ANOVA and  
Dunnett’s post-test (*, p < 0.05; **, p < 0.01 and ***, p < 0.001).  
  
Figure 4 – Silencing of the TP53-i9 alternatively spliced β and γ isoforms impairs IAV 
replication. A549 cells were treated twice with either the control non-specific si-RNA (sictrl) 
or a specific si-RNA targeting the p53β and p53γ spliced isoforms, as illustrated in (A). Twenty-
four hours after the last si-RNA treatment, cells were infected with H3N2 virus at MOI of 0.1 
or 0.01. Supernatants were harvested at 24 h intervals over 3 days, and the viral replication was 
determined by endpoint TCID50 titration in MDCK cells (measured in quadruplicate in two 
independent experiments) (B). Cells lysates were harvested before infection (T=0) or at 72 hpi 
to quantify p53total and p53β mRNA expression levels by RTqPCR, normalized on actin 
expression (C). Cellular and viral proteins were detected in western blot (D). # and ## indicate 
short and long exposure respectively. Data represent independent experimental duplicates. 
Mean values +/- standard deviation are shown, and statistical tests compared each condition 
with the si-ctrl T=0 condition using two-way ANOVA (*, p < 0.05; **, p < 0.01).  
  
Figure 5 – The silencing of CPSF4 impacts IAV replication in a partially p53-dependent 
manner. A549 (A-C) or H1299 (D-F) cells were treated twice with either a control nonspecific 
siRNA (si-ctrl) or a pool of siRNAs targeting cellular CPSF4. Twenty-four hours after the last 
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treatment, cells were infected with H3N2 at MOI of 0.1 or 0.01. Supernatants were harvested 
at 24 h intervals over 3 days, and the viral kinetics in A549 cells (A) or H1299 cells (D) were 
determined by endpoint TCID50 titration in MDCK cells (measured in quadruplicate in two 
independent experiments). Cells lysates were harvested before infection (T=0) or at 72 hpi and 
cellular p53 and CPSF4, together with viral NP and NS1 proteins were detected by western blot 
(B,E). CPSF4 mRNA expression was also measured by RT-qPCR (normalized against GAPDH 
expression) at T=0 and 72 hpi (C,F). All data represent independent experimental duplicates. 
Mean values +/- standard deviation are shown, and statistical tests compared each condition 
with the si-ctrl at T=0 control using two-way ANOVA (*, p < 0.05; **, p < 0.01 and ***, p < 
0.001).  
  
Figure 6 –p53β and p53γ isoforms together with CPSF4 contribute to p53-mediated IFN-
I-response to IAV infection and extracellular stresses. A549 cells were treated twice with 
nonspecific si-RNA (si-ctrl), a siRNA targeting all p53 forms (si-P53tot, figure 5A), a specific 
siRNA targeting alternatively spliced p53β and p53γ isoforms (si-P53i9, figure 5A), a pool of 
si-RNAs targeting CPSF4 (si-CPSF4) or a combination of si-P53i9 and si-CPSF4. Twenty-four 
hours later, cells were infected with H3N2 at MOI of 4 (A+C)) or added extracellular poly (I:C) 
to induce a stress through TLR3 activation (B+D). (A,B) Supernatants were harvested 24 h after 
treatment IFN-α and IFN-β levels were quantified. (C) Cell lysates were also collected to 
monitor infection, si-RNA efficiency and type I IFN response via STAT1 phosphorylation by 
western blot. # and ## indicate short and long exposure respectively with DO-1 antibody. Mean 
values +/- standard deviation of experimental duplicate are shown and two-way ANOVA test 
compared each condition with the si-ctrl condition (*, p < 0.05; **, p < 0.01 and ***, p < 0.001).  
  
Figure 7 – Working model of interplay between IAV NS1 protein, cellular factor CPSF4 
and TP53 splicing. During IAV infection, IAV NS1 inhibits p53 transcriptional activity via its 
interaction with p53, but also via the modulation of TP53 splicing by “buffering” the function 
of CPSF4 in mRNA maturation and splicing. As a result, the spliced p53 isoform modulation 
of p53 transcriptional activity, and notably p53-mediated antiviral responses, coupled to the 
cellular impact of CPSF4 blockade, positively influence viral production.  
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921 When NS1 is mutated, preventing its binding to CPSF4, this regulation loop is impaired, and 922 
the antiviral response is increased, limiting viral production.  
  
  
   
  
  
  
  
